Total
0
Shares
AnteoTech (ASX:ADO) - CEO, Derek Thomson
CEO, Derek Thomson
Sourced: AnteoTech
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • AnteoTech (ADO) signs a distribution agreement with UC Biosciences for its EuGeni Reader platform and its COVID-19 test in the Philippines
  • The three-year agreement gives UC Biosciences exclusive sales rights in the Philippines
  • The parties will jointly review and respond to public and private tender opportunities
  • On the market, AnteoTech is up 13.5 per cent and is trading at 21 cents per share

AnteoTech (ADO) has signed a distribution agreement with UC Biosciences for its EuGeni Reader platform and its COVID-19 test in the Philippines.

UC Bioscience is headquartered in Singapore and has offices in Malaysia, Myanmar and Philippines.

The three-year agreement gives UC Biosciences exclusive sales rights in the Philippines.

The parties will jointly review and respond to public and private tender opportunities.

AnteoTech CEO Derek Thomson is pleased to welcome UC Biosciences as a distribution partner.

“[UC Biosciences] has over 40 years’ experience as a distributor, with a strong sales network. The Philippines has a population of over 100 million people and have used rapid antigen testing as a tool within their pandemic response.,” he said.

“With [UC Biosciences] coming on board, we have expanded our distribution network and coverage across South East Asia. Over the coming weeks we will work with [UC Biosciences] to ensure we have the required regulatory approvals in place to commence selling into the Philippines market.”

In July, the company signed a distribution agreement with Abacus for its products in Australia, New Zealand and Pacific Islands.

On the market, AnteoTech is up 13.5 per cent and is trading at 21 cents per share at 11:42 am AEST.

ADO by the numbers
More From The Market Herald
(ASX:ATH) -

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.